Investment Thesis

and prompt an increase in position size.

Competitive Moat

characterized by its extensive portfolio of patented drugs and strong pipeline of investigational therapies, which provide significant intangible assets and regulatory advantages. The company’s scale and established market presence allow it to leverage economies of scale in manufacturing and distribution, further enhancing its competitive position. Key threats include emerging biosimilars targeting its blockbuster drugs and the potential for accelerated competition in oncology from both established players and biotech startups.

Growth Engine

Future revenue growth for BMY is expected to stem from its expanding oncology portfolio and new drug approvals in immunology and hematology, which are projected to address a total addressable market (TAM) exceeding $50 billion. The recent FDA approvals for therapies like Breyanzi and Zeposia, along with promising data from late-stage trials, suggest that BMY is well-positioned to capture market share. Additionally, BMY's international expansion efforts, particularly in emerging markets, are likely to drive organic growth, as healthcare access continues to improve.